Researcher
Heleen Van Acker
- Keywords:Pharmacy and pharmacology
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal chemistry, Medicinal products, Pharmaceutical analysis and quality assurance, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences, Other medical and health sciences
Affiliations
- Laboratory for Experimental Hematology (LEH) (Research group)
Member
From1 Jan 2019 → 12 May 2019 - Vaccine & Infectious Disease Institute (VAXINFECTIO) (Research group)
Member
From1 Jan 2014 → 31 Dec 2018
Projects
1 - 3 of 3
- Harnessing the expression of interleukin-15 and CD56 in immunotherapeutic strategies combating leukemia: a functional and mechanistic characterizationFrom1 Oct 2017 → 12 May 2019Funding: FWO fellowships
- Harnessing the expression of interleukin-15 and CD56 in immunotherapeutic strategies combating leukemia: a functional and mechanistic characterization.From1 Oct 2015 → 30 Sep 2017Funding: FWO fellowships
- Preclinical development of an innovative immune therapy based on CD56 + dendritic cells and interleukin-15: recruitment of the innate immune system in the fight against cancer.From1 Jan 2014 → 30 Sep 2015Funding: IWT personal funding - strategic basic research grants
Publications
1 - 10 of 19
- Rothia mucilaginosa is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease(2022)
Authors: Charlotte Rigauts, Juliana Aizawa Porto de Abreu, Steven L. Taylor, Geraint B. Rogers, Matthias Govaerts, Paul Cos, Lisa Ostyn, Sarah Sims, Eva Vandeplassche, Mozes Sze, et al.
- Chimeric antigen receptor-modified T cell therapy in multiple myeloma(2019)
Authors: Marijke Timmers, Gils Roex, Yuedi Wang, Diana Campillo Davó, Vigor Van Tendeloo, Yiwei Chu, Zwi Berneman, Feifei Luo, Heleen Van Acker, Sébastien Anguille
- Dendritic cell-based immunotherapy of acute myeloid leukemia(2019)
Authors: Heleen Van Acker, Maarten Versteven, Felix S. Lichtenegger, Gils Roex, Diana Campillo Davó, Eva Lion, Marion Subklewe, Vigor Van Tendeloo, Zwi Berneman, Sébastien Anguille
- CD56 homodimerization and participation in anti-tumor immune effector cell functioning(2019)
Authors: Heleen Van Acker, Zoë Van Acker, Maarten Versteven, Peter Ponsaerts, Daniela Pende, Zwi Berneman, Sébastien Anguille, Vigor Van Tendeloo, Evelien Smits
- The role of the common gamma-chain family cytokines in $\gamma\delta$ T cell-based anti-cancer immunotherapy(2018)
Authors: Heleen Van Acker, Diana Campillo Davó, Gils Roex, Maarten Versteven, Evelien Smits, Vigor Van Tendeloo
Pages: 54 - 64 - Interleukin-15-cultered dendritic cells enhance anti-tumor gamme delta T cell functions through IL-15 secretion(2018)
Authors: Heleen Van Acker, Sébastien Anguille, Hans De Reu, Evelien Smits, Vigor Van Tendeloo
- BDCA1+CD14+ immunosuppressive cells in cancer, a potential target?(2018)
Authors: Thomas J. van Ee, Heleen Van Acker, Tom G. van Oorschot, Vigor Van Tendeloo, Evelien Smits, Ghaith Bakdash, Gerty Schreibelt, I. Jolanda M. de Vries
- Harnessing gamma delta T cells, interleukin-15 and CD56 in immunotherapeutic strategies combating leukemia(2018)
Authors: Heleen Van Acker, Vigor Van Tendeloo, Evelien Smits
Number of pages: 237 - CD56 in the immune system(2017)
Authors: Heleen Van Acker, Anna Capsomidis, Evelien Smits, Vigor Van Tendeloo
- Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells(2017)
Authors: Heleen Van Acker, Ottavio Beretta, Sébastien Anguille, Lien De Caluwe, Angela Papagna, Johan Van den Bergh, Yannick Willemen, Herman Goossens, Zwi Berneman, Vigor Van Tendeloo, et al.
Pages: 13652 - 13665